9C5S
| Disulfide-linked, antiparallel p53-derived peptide dimer (CV1) | Descriptor: | Cellular tumor antigen p53, SULFATE ION | Authors: | Vithanage, N, Kreitler, D.K, DiGiorno, M.C, Victorio, C.G, Sawyer, N, Outlaw, V.K. | Deposit date: | 2024-06-06 | Release date: | 2024-06-26 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.01 Å) | Cite: | Structural Characterization of Disulfide-Linked p53-Derived Peptide Dimers. Res Sq, 2024
|
|
5MHC
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide | Descriptor: | 14-3-3 protein sigma, CALCIUM ION, LYS-LEU-MET-PHE-LYS-TPO-GLU-GLY-PRO-ASP-SER-ASP, ... | Authors: | Andrei, S, Ottmann, C, Leysen, S. | Deposit date: | 2016-11-24 | Release date: | 2017-10-04 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Small-molecule stabilization of the p53 - 14-3-3 protein-protein interaction. FEBS Lett., 591, 2017
|
|
3D06
| Human p53 core domain with hot spot mutation R249S (I) | Descriptor: | Cellular tumor antigen p53, ZINC ION | Authors: | Rozenberg, H, Suad, O, Shimon, L.J.W, Frolow, F, Shakked, Z. | Deposit date: | 2008-05-01 | Release date: | 2009-01-20 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations J.Mol.Biol., 385, 2009
|
|
8UQR
| Crystal structure of the human p53 tetramerization domain | Descriptor: | Cellular tumor antigen p53 | Authors: | Wahba, H.M, Sakaguchi, S, Nakagawa, N, Wada, J, Kamada, R, Sakaguchi, K, Omichinski, J.G. | Deposit date: | 2023-10-24 | Release date: | 2023-12-20 | Method: | X-RAY DIFFRACTION (1.22 Å) | Cite: | Highly Similar Tetramerization Domains from the p53 Protein of Different Mammalian Species Possess Varying Biophysical, Functional and Structural Properties. Int J Mol Sci, 24, 2023
|
|
6GGC
| |
6SHZ
| p53 cancer mutant Y220C | Descriptor: | 1,2-ETHANEDIOL, Cellular tumor antigen p53, GLYCEROL, ... | Authors: | Joerger, A.C, Structural Genomics Consortium (SGC) | Deposit date: | 2019-08-08 | Release date: | 2020-02-19 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.24 Å) | Cite: | Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm. Acs Chem.Biol., 15, 2020
|
|
4MZI
| Crystal structure of a human mutant p53 | Descriptor: | Cellular tumor antigen p53, ZINC ION | Authors: | Emamzadah, S, Tropia, L, Vincenti, I, Falquet, B, Halazonetis, T.D. | Deposit date: | 2013-09-30 | Release date: | 2014-01-15 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (1.25 Å) | Cite: | Reversal of the DNA-Binding-Induced Loop L1 Conformational Switch in an Engineered Human p53 Protein. J.Mol.Biol., 426, 2014
|
|
6GGE
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9327 | Descriptor: | Cellular tumor antigen p53, ZINC ION, [9-ethyl-7-(5-methylthiophen-2-yl)carbazol-3-yl]methyl-methyl-azanium | Authors: | Joerger, A.C, Bauer, M.R. | Deposit date: | 2018-05-03 | Release date: | 2019-05-22 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.25000513 Å) | Cite: | A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. Future Med Chem, 11, 2019
|
|
3LW1
| Binary complex of 14-3-3 sigma and p53 pT387-peptide | Descriptor: | 14-3-3 protein sigma, CHLORIDE ION, GLYCEROL, ... | Authors: | Schumacher, B, Mondry, J, Thiel, P, Weyand, M, Ottmann, C. | Deposit date: | 2010-02-23 | Release date: | 2010-03-23 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (1.28 Å) | Cite: | Structure of the p53 C-terminus bound to 14-3-3: Implications for stabilization of the p53 tetramer Febs Lett., 584, 2010
|
|
6RL3
| Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface | Descriptor: | 14-3-3 protein sigma, 5-azanyl-4-phenyl-thiophene-2-carboximidamide, CHLORIDE ION, ... | Authors: | Genet, S, Wolter, M, Guillory, X, Somsen, B, Leysen, S, Patel, J, Castaldi, P, Ottmann, C. | Deposit date: | 2019-05-01 | Release date: | 2020-06-17 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Fragment-based Differential Targeting of PPI Stabilizer Interfaces. J.Med.Chem., 63, 2020
|
|
5O1E
| p53 cancer mutant Y220C im complex with compound MB577 | Descriptor: | 3-iodanyl-2-oxidanyl-5-prop-2-enoxy-4-pyrrol-1-yl-benzoic acid, Cellular tumor antigen p53, GLYCEROL, ... | Authors: | Joerger, A.C, Baud, M.G.J, Bauer, M.R, Fersht, A.R. | Deposit date: | 2017-05-18 | Release date: | 2018-05-09 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem, 152, 2018
|
|
8E7A
| Crystal structure of the p53 (Y107H) core domain orthorhombic P form | Descriptor: | Cellular tumor antigen p53, ZINC ION | Authors: | Lovell, S, Liu, L, Battaile, K.P, Miller, S, Karanicolas, J. | Deposit date: | 2022-08-23 | Release date: | 2023-05-17 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression. Cancer Discov, 13, 2023
|
|
7JGW
| Crystal structure of BCL-XL in complex with COMPOUND 1620116, CRYSTAL FORM 1 | Descriptor: | 6-[(8E)-8-{2-[4-(benzylcarbamoyl)-1,3-thiazol-2-yl]hydrazinylidene}-5,6,7,8-tetrahydronaphthalen-2-yl]-3-(2-phenylethoxy)pyridine-2-carboxylic acid, Bcl-2-like protein 1 | Authors: | Lee, M, Fairlie, W.D, Smith, B.J, Lee, E.F. | Deposit date: | 2020-07-19 | Release date: | 2021-02-24 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. Acs Infect Dis., 7, 2021
|
|
7B4N
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Human wild-type p53DBD bound to DNA and MQ: wt-DNA-MQ (II) | Descriptor: | (2~{R})-2-methyl-1-azabicyclo[2.2.2]octan-3-one, (2~{S})-2-methyl-1-azabicyclo[2.2.2]octan-3-one, Cellular tumor antigen p53, ... | Authors: | Rozenberg, H, Diskin-Posner, Y, Degtjarik, O, Shakked, Z. | Deposit date: | 2020-12-02 | Release date: | 2021-12-08 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.32 Å) | Cite: | Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat Commun, 12, 2021
|
|
5O1H
| p53 cancer mutant Y220C in complex with compound MB539 | Descriptor: | 3-iodanyl-2-oxidanyl-5-propylsulfanyl-4-pyrrol-1-yl-benzoic acid, Cellular tumor antigen p53, GLYCEROL, ... | Authors: | Joerger, A.C, Bauer, M.R, Baud, M.G.J, Fersht, A.R. | Deposit date: | 2017-05-18 | Release date: | 2018-05-09 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.32 Å) | Cite: | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem, 152, 2018
|
|
5O1C
| p53 cancer mutant Y220C in complex with compound MB184 | Descriptor: | 5-(4-fluorophenyl)-3-iodanyl-2-oxidanyl-4-pyrrol-1-yl-benzoic acid, Cellular tumor antigen p53, ZINC ION | Authors: | Joerger, A.C, Baud, M.G.J, Bauer, M.R, Fersht, A.R. | Deposit date: | 2017-05-18 | Release date: | 2018-05-09 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.32 Å) | Cite: | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem, 152, 2018
|
|
6GGB
| |
6GGF
| |
3ZME
| |
5G4N
| Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the small molecule stabilizer Phikan083 | Descriptor: | 1-[9-(2,2-difluoroethyl)-9H-carbazol-3-yl]-N-methylmethanamine, CELLULAR TUMOR ANTIGEN P53, GLYCEROL, ... | Authors: | Joerger, A.C, Bauer, M, Jones, R.N, Spencer, J. | Deposit date: | 2016-05-13 | Release date: | 2016-06-22 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of P53 Mutant Y220C Rescue Drugs. Acs Chem.Biol., 11, 2016
|
|
5AOK
| Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan7099 | Descriptor: | 5-[2-cyclopropyl-5-(1H-pyrrol-1-yl)-1,3-oxazol-4-yl]-1H-1,2,3,4-tetrazole, CELLULAR TUMOR ANTIGEN P53, DI(HYDROXYETHYL)ETHER, ... | Authors: | Joerger, A.C. | Deposit date: | 2015-09-10 | Release date: | 2015-12-16 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant P53. Structure, 23, 2015
|
|
6V4F
| Crystal Structure Analysis of Zebra Fish MDMX | Descriptor: | Protein Mdm4, SULFATE ION, Stapled Peptide LSQETF(0EH)DLWKLE(MK8)EN(NH2) | Authors: | Seo, H.-S, Dhe-Paganon, S. | Deposit date: | 2019-11-27 | Release date: | 2020-04-22 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Identification of a Structural Determinant for Selective Targeting of HDMX. Structure, 28, 2020
|
|
5O1G
| p53 cancer mutant Y220C in complex with compound MB487 | Descriptor: | 3-iodanyl-2-oxidanyl-5-(2-phenylethoxy)-4-pyrrol-1-yl-benzoic acid, Cellular tumor antigen p53, GLYCEROL, ... | Authors: | Joerger, A.C, Baud, M.G.J, Bauer, M.R, Fersht, A.R. | Deposit date: | 2017-05-18 | Release date: | 2018-05-09 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem, 152, 2018
|
|
5O1D
| p53 cancer mutant Y220C in complex with compound MB481 | Descriptor: | 3-iodanyl-2-oxidanyl-5-propoxy-4-pyrrol-1-yl-benzoic acid, Cellular tumor antigen p53, GLYCEROL, ... | Authors: | Joerger, A.C, Bauer, M.R, Baud, M.G.J, Fersht, A.R. | Deposit date: | 2017-05-18 | Release date: | 2018-05-09 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.36 Å) | Cite: | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem, 152, 2018
|
|
5AB9
| |